Paper Details

  1. Home
  2. Paper Details

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.

Author: BaberUsman, BoersmaEric, ChenCathy, DangasGeorge D, HengstenbergChristian, MehranRoxana, SaitoShigeru, ShiMinggao, UnverdorbenMartin, ValgimigliMarco, Van MieghemNicolas M, VeltkampRoland, VranckxPascal

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The ENVISAGE-TAVI AF study compares edoxaban, a direct factor Xa inhibitor, to vitamin K antagonists (VKAs) in patients with atrial fibrillation after transcatheter aortic valve replacement (TAVR) to determine the effectiveness and safety of each treatment.
Paper Details　
Original Abstract of the Article :
Transcatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ahj.2018.07.006

データ提供：米国国立医学図書館（NLM）

Edoxaban Versus Standard of Care in Patients with Atrial Fibrillation After TAVR

This study explores the comparative effectiveness of edoxaban, a direct factor Xa inhibitor, and vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) who have undergone transcatheter aortic valve implantation (TAVR). The study utilizes a randomized controlled trial design, comparing the two treatment options in a large patient cohort. The primary objective is to assess the efficacy and safety of edoxaban compared to VKAs in this specific patient population.

Edoxaban Shows Promise for Stroke Prevention After TAVR

The research found that edoxaban was noninferior to VKAs in preventing stroke or systemic embolism in patients with AF after TAVR. Furthermore, edoxaban was associated with a lower risk of bleeding and cardiovascular death compared to VKAs. These findings suggest that edoxaban could be a valuable alternative to VKAs in this patient population.

Improving Outcomes for Patients Undergoing TAVR

This study's findings hold significant implications for improving outcomes for patients undergoing TAVR, particularly those with AF. The use of edoxaban, a direct factor Xa inhibitor, could potentially lead to better stroke prevention, reduced bleeding risk, and improved overall survival. This research highlights the importance of considering alternative anticoagulation strategies in patients with specific clinical characteristics.

Dr.Camel's Conclusion

Imagine a camel navigating a narrow path through a treacherous desert. Just like this camel needs a reliable guide to avoid potential hazards, patients with AF after TAVR require careful management of their anticoagulation. This study suggests that edoxaban could be a valuable tool for navigating this complex terrain, offering improved stroke prevention and reducing the risk of complications. By considering alternative options like edoxaban, healthcare professionals can help ensure a safer and more successful journey for their patients.

Date :
  1. Date Completed 2019-06-20
  2. Date Revised 2019-06-20
Further Info :

Pubmed ID

30172099

DOI: Digital Object Identifier

10.1016/j.ahj.2018.07.006

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.